OMNIX MEDICAL: UN PAPILLON CONTRE ACINETOBACTER BAUMANNII

STUDY: In Vitro Antimicrobial Activity of OMN51 Against MDR Pseudomonas aeruginosa Isolated from People with Cystic Fibrosis

Omnix Medical tested its novel antimicrobial peptide, OMN51, on clinical isolates of multi-drug-resistant Pseudomonas aeruginosa collected from cystic fibrosis patients, in collaboration with Beilinson – Rabin Medical Center.

Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials

“Antibacterial agents active against Gram‑Negative Bacilli in Phase I, II, or III Clinical Trials,” by David L. Paterson, surveys nearly 50 investigational therapeutics—28 small‑molecule antibiotics and 21 non‑traditional modalities—now in the clinic. The review highlights

REVIEW: Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Acinetobacter baumannii complex (ABC) causes severe infections such as pneumonia and septic shock, yet therapeutic options—particularly for carbapenem‑resistant strains (CRAB)—remain scarce amid rising antimicrobial resistance. This

OMNIX MEDICAL: UN PAPILLON CONTRE ACINETOBACTER BAUMANNII

More To Explore

STUDY: In Vitro Antimicrobial Activity of OMN51 Against MDR Pseudomonas aeruginosa Isolated from People with Cystic Fibrosis

Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials

REVIEW: Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Contact Us

Reach US